505b2 pathway and how it compares with other FDA drug routes

The 505b2 pathway for FDA drug approval

The 505b2 pathway is an FDA new drug application (NDA) route that relies partly on investigations outside the applicant's program. At least some relied-upon safety or effectiveness investigations were not conducted by or for the applicant, who lacks a right of reference or use. Both conditions define a 505(b)(2) application under 21 CFR 314.3.

For a modified approved drug, the sponsor must support its proposed product and the changes it makes. Reliance on earlier findings does not automatically remove the need for new studies. The application remains an NDA, with product-specific evidence requirements.

What makes an application a 505(b)(2) NDA?

The definition turns on evidence and the applicant's rights to use it. It does not turn solely on whether the drug is a reformulation or contains an already approved ingredient. A right of reference means authority to use an investigation for NDA approval. That includes making underlying raw data available for FDA audit when necessary. These terms have specific regulatory definitions.

A sponsor that holds a right of reference to another party's investigation does not meet the b2 definition merely because someone else conducted it. The absence of that right is part of the test. This distinction matters when deciding whether a program is a stand-alone NDA or a reliance-based NDA under section 314.3.

For an approved-drug modification, the applicant must identify each listed drug whose FDA safety and effectiveness finding it relies upon. Specified information can then be satisfied by reference. This relies on FDA's previous finding, without granting access to another sponsor's confidential dossier.

505(b)(1) vs 505(b)(2) vs ANDA

The usual comparison needs one qualification: a 505(b)(2) application is itself an NDA submitted under section 505(b)(1). In practice, "505(b)(1) vs 505(b)(2)" contrasts a stand-alone NDA with a reliance-based NDA. The CFR definition places both within the NDA framework.

The NDA distinctions follow the application definitions. The ordinary ANDA requirements address sameness in active ingredients, dosage form, strength, route and conditions of use, subject to permitted exceptions. They also address bioequivalence. See 314.92 and 314.94.

An ANDA does not require identity in every inactive ingredient. The definition of pharmaceutical equivalents expressly allows different inactive ingredients. A formulation change alone therefore does not establish that a sponsor needs the 505(b)(2) regulatory pathway.

Which modified drugs may fit the pathway?

The regulation gives a new indication and a new dosage form as examples of listed-drug modifications. Section 314.54 addresses such changes where investigations beyond bioavailability or bioequivalence are essential to approval. An ANDA cannot be approved for a new indication or other changes requiring such investigations. These are examples of potential 505(b)(2) products, not a rule that every dosage-form change requires b2.

Some changes in route, dosage form or strength can instead proceed through an ANDA after an approved suitability petition. FDA will not approve that petition if investigations are needed to demonstrate the differing product's safety or effectiveness. The suitability-petition rules therefore matter before assigning a modified product to an NDA route.

Nor can a sponsor freely choose b2 for an ANDA-eligible duplicate. FDA may refuse to file a 505(b)(2) application for a duplicate eligible for approval under section 505(j). Needing evidence beyond BA/BE also does not, by itself, settle the NDA route. A stand-alone NDA remains a separate possibility, depending on the investigations and rights involved.

Another limit is narrower than it may first appear. Section 314.54(b) excludes products whose only difference is lower absorption or unintentionally slower absorption. It does not categorically exclude intentional modified-release products. The exclusion turns on "unintentionally".

What evidence does a sponsor still need?

For a qualifying modification, the NDA must contain the information needed to support that modification. The applicant must identify the relied-upon listed drugs and provide additional safety or effectiveness information as needed. Those obligations remain even when FDA has already approved the earlier product. They appear in 314.54(a).

Start with the proposed product and its differences from the listed drug. For each difference, establish what the earlier finding supports and what evidence the proposed product still needs. This follows the regulation's modification-specific evidence requirement. It avoids assuming that a prior approval answers every question about a changed product.

Keep two questions separate when planning the evidence: what supports the approved drug, and what supports the proposed change? Identification of the listed drug addresses reliance. It does not, on its own, establish the changed product's safety or effectiveness. The application requirements address both reliance and the additional information needed for the modification.

Manufacturing information remains part of the application. Section 314.54(a)(1)(i) includes a proposed or actual master production record, including equipment used for a commercial lot. Reliance on an earlier finding does not replace product-specific manufacturing information.

There is no fixed study recipe in these provisions. They do not establish that every b2 program needs new efficacy trials, or that one BA/BE study always suffices. The unresolved work is product-specific: determine which additional investigations are needed to support approval under 314.54(a)(1)(ii).

Patents and exclusivity still affect the application

Reliance does not bypass patent obligations. Section 314.54 requires applicable patent information and certifications or statements concerning relevant patents for the relied-upon listed drugs. Include those obligations in route planning alongside the evidence requirements.

Five-year new-chemical-entity exclusivity generally bars submission of a same-active-moiety 505(b)(2) NDA or ANDA. A specified paragraph IV exception permits submission after four years. That is a submission rule, not a promise of approval in either year. The distinction is set out in 314.108(b)(2).

Three-year exclusivity is also conditional. Qualifying new clinical investigations, other than bioavailability studies, must be conducted or sponsored by the applicant and essential to approval. Its blocking scope concerns the protected approval conditions or change. It is neither automatic for every b2 approval nor blanket protection for every product containing the drug. See 314.108(b)(4)-(5).

Use the route rules without assuming a shortcut

FDA's May 2019 final guidance addresses the choice between ANDA and 505(b)(2). An August 18, 2026 notice announced revised draft guidance that would replace it when finalized. That notice does not itself replace the final guidance.

For a regulatory team, the route decision starts with ANDA eligibility, the proposed changes and the rights to supporting investigations. Neither the evidence rules nor exclusivity provisions promise a standard development timeline or trial-free program. Base the plan on what the proposed product needs.

RegAffairs AI has a source-linked answer on modified-drug applications and generic applications.

Related guides

• 21 CFR 314.70 reporting routes for approved drug changes
• New drug application requirements and the FDA review process
• What is an ANDA? FDA generic drug application requirements
• 21 CFR 211 requirements for finished pharmaceutical drugs